The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcome for gastrointestinal cancers with polymerase epsilon mutations treated with immunotherapy.
 
Limin Zhu
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Dialectica; Dialectica; Dialectica; Dialectica; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sumitomo Group
Consulting or Advisory Role - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Clearlight Diagnostics; Clearlight Diagnostics; Clearlight Diagnostics; Clearlight Diagnostics; DarwinHealth; DarwinHealth; DarwinHealth; DarwinHealth; Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Genentech; Genentech; Genentech; Genentech; Immunomedics; Immunomedics; Immunomedics; Immunomedics; Inflection Biosciences; Inflection Biosciences; Inflection Biosciences; Inflection Biosciences; Mersana; Mersana; Mersana; Mersana; Origimed; Origimed; Origimed; Origimed; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Samsung Bioepis; Samsung Bioepis; Samsung Bioepis; Samsung Bioepis; Seagen; Seagen; Seagen; Seagen; Silverback Therapeutics; Silverback Therapeutics; Silverback Therapeutics; Silverback Therapeutics; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Xencor; Xencor; Xencor; Xencor
Speakers' Bureau - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma
Research Funding - Abbvie; Abbvie; Abbvie; Abbvie; Aileron Therapeutics; Aileron Therapeutics; Aileron Therapeutics; Aileron Therapeutics; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Boehringer Ingelheim (I); Boehringer Ingelheim (I); Boehringer Ingelheim (I); Boehringer Ingelheim (I); Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Calithera Biosciences; Curis; Curis; Curis; Curis; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; eFFECTOR Therapeutics; eFFECTOR Therapeutics; eFFECTOR Therapeutics; eFFECTOR Therapeutics; Genentech; Genentech; Genentech; Genentech; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; PUMA Biotechnology; PUMA Biotechnology; PUMA Biotechnology; PUMA Biotechnology; Seagen; Seagen; Seagen; Seagen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Zymeworks; Zymeworks; Zymeworks; Zymeworks
Travel, Accommodations, Expenses - Seagen; Seagen; Seagen; Seagen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Vijaykumar Holla
No Relationships to Disclose
 
Taebeom Kim
No Relationships to Disclose
 
Kenna Rael Shaw
Research Funding - Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Tempus (Inst); Tempus (Inst); Tempus (Inst); Tempus (Inst)
 
Ken Chen
No Relationships to Disclose
 
Mark Routbort
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; MolecularMatch; MolecularMatch; MolecularMatch; Navire; Navire; Navire; Navire
Consulting or Advisory Role - Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer Health; Bayer Health; Bayer Health; Bayer Health; Biocartis; Biocartis; Biocartis; Biocartis; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Genentech; Genentech; Genentech; Genentech; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Navire; Navire; Navire; Navire; Novartis; Novartis; Novartis; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Redx Pharma; Redx Pharma; Redx Pharma; Redx Pharma; Roche; Roche; Roche; Roche; Symphogen; Symphogen; Symphogen; Symphogen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
 
Michael J. Overman
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; MedImmune; MedImmune; MedImmune; MedImmune; Novartis; Novartis; Novartis; Novartis; Promega; Promega; Promega; Promega; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MedImmune; MedImmune; MedImmune; MedImmune; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche